Leu-AMS, a leucine analogue and potent inhibitor of leucyl-tRNAsynthetase (LRS) with an IC50 of 22.34 nM, exhibits cytotoxic effects in both cancer and normal cells and hampers bacterial growth. It specifically inhibits LRS's catalytic activity without impacting the leucine-induced activation of mTORC1.